Antonio Marra, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn:
“Happy to see our paper finally out in AACR Journals Clinical Cancer Research!
We analyzed clinical and genomic data from >6,000 patients in the MSK Breast Translational database. CCNE1 amplification defines a subset of breast cancers with high genomic instability and poor clinical outcomes, supporting its role as a potential biomarker for novel therapeutic strategies.
With many new agents in development, including CDK2 and PKMYT1 inhibitors and other synthetic-lethality approaches, CCNE1 status may identify a subset of patients with advanced breast cancer who could benefit from these drugs.
Huge thanks to my friends and colleagues Ezra Rosen and Luca Boscolo-Bielo, who co-led this work, and to the great team at Memorial Sloan Kettering Cancer Center for the wonderful collaboration that made this possible.”
Title: CCNE1 Amplification Confers Poor Outcomes and Therapeutic Resistance in Breast Cancer.
Authors: Antonio Marra, Luca Boscolo-Bielo, Pier Selenica, Yingjie Zhu, Anton Safonov, Andrea M. Gazzo, Giuseppe Curigliano, Dara Ross, Britta Weigelt, Alison M. Schram, Jorge S. Reis-Filho, Mark E. Robson, Sarat Chandarlapaty, Pedram Razavi, Ezra Y. Rosen.
You can also read: Beyond CDK4/6: Next-Generation Cell-Cycle Inhibitors May Redefine HR-Positive Breast Cancer Treatment.
